Merck: presents phase 3 results for Keytruda
(CercleFinance.com) - Merck and Eisai are presenting results from the phase 3 trial evaluating KEYTRUDA plus LENVIMA, versus LENVIMA alone, in patients with unresectable hepatocellular carcinoma at the European Society for Medical Oncology (ESMO) 2022 Congress, which is currently being held in Paris.
In the final analysis of the trial, a trend towards improvement in one of the two primary endpoints of the study, overall survival, was observed in patients treated with KEYTRUDA plus LENVIMA compared to LENVIMA monotherapy; however, the results were not statistically significant according to the pre-specified statistical design.
In addition, treatment with KEYTRUDA plus LENVIMA resulted in a trend towards improvement in the other primary endpoint of the trial, progression-free survival (PFS), compared to LENVIMA monotherapy.
Merck said that the median overall survival of 21.2 months observed with KEYTRUDA plus LENVIMA provides critical guidance for further research into the potential role of this combination.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
In the final analysis of the trial, a trend towards improvement in one of the two primary endpoints of the study, overall survival, was observed in patients treated with KEYTRUDA plus LENVIMA compared to LENVIMA monotherapy; however, the results were not statistically significant according to the pre-specified statistical design.
In addition, treatment with KEYTRUDA plus LENVIMA resulted in a trend towards improvement in the other primary endpoint of the trial, progression-free survival (PFS), compared to LENVIMA monotherapy.
Merck said that the median overall survival of 21.2 months observed with KEYTRUDA plus LENVIMA provides critical guidance for further research into the potential role of this combination.
Copyright (c) 2022 CercleFinance.com. All rights reserved.